
Kala Bio Inc. (NASDAQ: KALA) stock is down on Monday after the company halted development of its experimental treatment for a specific eye condition.
The company had a session volume of 14.04 million compared to the average volume of 216.47 thousand, according to data from Benzinga Pro.